Can-Fite BioPharma Ltd. reported earnings results for the nine months ended September 30, 2023. For the nine months, the company reported sales was USD 0.588 million compared to USD 0.613 million a year ago. Net loss was USD 5.98 million compared to USD 7.15 million a year ago.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
3 ILa | +7.14% | +7.14% | +15.38% |
Jun. 05 | Can-Fite Biopharma Ltd. Updates on Its Advanced Liver Cancer Pivotal Phase 3 Study | CI |
May. 12 | Transcript : Can-Fite BioPharma Ltd. - Special Call |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+15.38% | 12.09M | |
+0.99% | 91.72B | |
0.00% | 39.44B | |
-8.52% | 34.47B | |
+64.77% | 26.7B | |
-17.37% | 15.13B | |
-5.99% | 13.27B | |
-10.69% | 11.74B | |
-47.78% | 10.54B | |
+8.09% | 9.41B |
- Stock Market
- Equities
- CANF Stock
- News Can-Fite BioPharma Ltd.
- Can-Fite BioPharma Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023